



ASX & Media Release

Pilot Study Leads to New Pre-Clinical Collaboration on PAT-DX1

Melbourne, Australia; 17 May, 2018: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, is pleased to announce that following the completion of a pilot study, it has initiated a research and development collaboration that brings together experts from Yale School of Medicine in New Haven, Connecticut and Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts.

The pilot study showed that PAT-DX1 has antitumor activity in an orthotopic, immune-competent mouse model of triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The expanded research program will be led by Dr. James Hansen of Yale and Drs. Gerburg Wulf and Jaymin Patel of BIDMC, and will further investigate PAT-DX1 in BIDMC's orthotopic, immune-competent mouse model of TNBC.

Dr. Hansen is an expert in cell-penetrating antibodies and is inventor of the Deoxymab technology. Dr. Wulf has significant experience in the development and testing of new drug combinations that may improve outcomes in TNBC. Dr. Patel's translational research in the field of breast cancer spans nanoparticle technology, genomic instability, DNA damage repair (DDR), tumor targeting and personalized medicine.

"Patrys is delighted to continue our work with Dr. Hansen and to establish new collaborations with Dr. Patel and Dr. Wulf, all of them outstanding clinician-researchers whose expertise spans from the laboratory to the clinic. The opportunity to build on the successful pilot study and to further investigate PAT-DX1 in an immunocompetent mouse model of TNBC is timely, following the successful completion of the PAT-DX1 orthotopic glioblastoma study completed at Yale University in March," said Dr. James Campbell, Chief Executive Officer and Managing Director of Patrys.

"Patrys' novel position in the field of DNA damage repair antibody therapeutics is increasingly being recognized, resulting in collaborations such as this one between the company, Yale University and the Beth Israel Deaconess Medical Center", added Dr. Campbell

Patrys will make a statement on the research findings upon completion and publication of the study.



About Deoxymab 3E10, PAT-DX1 and PAT-DX1-NP

Deoxymab 3E10 is a DNA damage-repair (DDR) antibody that was first identified in lupus as an autoantibody that bound to normal cells. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has single agent therapeutic potential and has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumors.

Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP) towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Treatment with PAT-DX1 has been shown to significantly improve survival in an orthotopic model of glioblastoma. PAT-DX1 has also been shown to work synergistically with the approved PARP inhibitor, olaparib. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

Patrys' rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialize as anti-cancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.

-Ends-

For further information, please contact:

Patrys Limited:
James Campbell
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:
Ben Walsh
WE Buchan
P: +61 2 9237 2801
bwalsh@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.